Northwest Biotherapeutics (OTCMKTS:NWBO) and Regeneron Pharmaceuticals (NASDAQ:REGN) Head-To-Head Review

Northwest Biotherapeutics (OTCMKTS:NWBO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Insider & Institutional Ownership

0.0% of Northwest Biotherapeutics shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.4% of Northwest Biotherapeutics shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Northwest Biotherapeutics has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Northwest Biotherapeutics and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	0.00
Regeneron Pharmaceuticals	0	10	16	1	2.67

Regeneron Pharmaceuticals has a consensus target price of $797.75, suggesting a potential upside of 1.71%. Given Regeneron Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Northwest Biotherapeutics.

Profitability

This table compares Northwest Biotherapeutics and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-2,931.73%	N/A	-79.26%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Earnings and Valuation

This table compares Northwest Biotherapeutics and Regeneron Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.38 million	224.59	-$60.16 million	($18.23)	-0.01
Regeneron Pharmaceuticals	$14.34 billion	5.63	$4.50 billion	$40.46	19.39

Regeneron Pharmaceuticals has higher revenue and earnings than Northwest Biotherapeutics. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Northwest Biotherapeutics on 14 of the 15 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.